Compare DKL & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DKL | WGS |
|---|---|---|
| Founded | 2012 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Retail: Computer Software & Peripheral Equipment |
| Sector | Energy | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.7B |
| IPO Year | 2012 | 2020 |
| Metric | DKL | WGS |
|---|---|---|
| Price | $54.79 | $86.34 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $53.67 | ★ $120.71 |
| AVG Volume (30 Days) | 199.8K | ★ 718.4K |
| Earning Date | 04-29-2026 | 05-04-2026 |
| Dividend Yield | ★ 8.52% | N/A |
| EPS Growth | N/A | ★ 62.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $427,539,000.00 |
| Revenue This Year | $2.73 | $29.98 |
| Revenue Next Year | $6.82 | $25.92 |
| P/E Ratio | $17.62 | ★ N/A |
| Revenue Growth | N/A | ★ 39.97 |
| 52 Week Low | $42.51 | $32.21 |
| 52 Week High | $61.50 | $170.87 |
| Indicator | DKL | WGS |
|---|---|---|
| Relative Strength Index (RSI) | 48.82 | 66.14 |
| Support Level | $54.14 | $81.55 |
| Resistance Level | $60.75 | $96.34 |
| Average True Range (ATR) | 1.18 | 4.09 |
| MACD | -0.18 | 0.62 |
| Stochastic Oscillator | 46.49 | 76.01 |
Delek Logistics Partners LP owns and operates logistics and marketing assets for crude oil and intermediate and refined products. The company's segment includes gathering and processing; wholesale marketing and terminalling; storage and transportation and investment in pipeline joint ventures. It generates maximum revenue from the wholesale marketing and terminalling segment, which provides marketing services for the refined products output of the Delek Holdings' refineries, engages in wholesale activity at its terminals and terminals owned by third parties, whereby it purchases light product for sale and exchange to third parties, and provides terminalling services at its refined products terminals to independent third parties and Delek Holdings.
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.